Research Studies

Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For more than 50 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy.  At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.

Choosing to participate in a study is an important personal decision. Are you interested in participating in a study?  Talk with your doctor and family members or friends about deciding to join a study.

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal)

Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Sponsor: River 3 Renal

Indication: Alport Syndrome

Primary Investigator: Ankit Mehta, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus)

Protocol Name: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Sponsor: Amicus

Indication: Fabry Disease

Primary Investigator: Ankit Mehta, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)

Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

Sponsor: Dimerix B

Indication: FSGS

Primary Investigator: Kim Rice, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex)

Protocol Name: Phase 2/​3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease

Sponsor: Vertex

Indication: APOL1-Mediated Proteinuric Kidney Disease

Primary Investigator: Bernard Fischbach, MD

Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (Vitaeris)

Protocol Name: IMAGINE: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Sponsor: Vitaeris

Indication: Post Transplant – Chronic Active Antibody Mediated Rejection

Primary Investigator: Bernard Fischbach, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (Boehringer Ingelheim)

Protocol Name: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis

Sponsor: Boehringer Ingelheim

Indication: FSGS

Primary Investigator: Anupkumar Shetty, MD

Location: Charlton Office, 2651 Bolton Boone Drive, DeSoto, TX 75115

DETAILS >

Ziltivekimab Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (Novo Nordisk)

Protocol Name: ZEUS – A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Sponsor: Novo Nordisk

Indication: Dual Diagnosis of Chronic Kidney Disease & Cardiovascular Disease

Primary Investigator: Ankit Mehta, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain (Sanofi-Aventis)

Protocol Name: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Adult Participants With Fabry Disease (PERIDOT)

Sponsor: Sanofi-Aventis

Indication: Fabry Disease

Primary Investigator: Ankit Mehta, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal)

Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Sponsor: River 3 Renal

Indication: Focal segmental glomerulosclerosis (FSGS)

Primary Investigator: Ankit Mehta, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >

Affinity: Atrasentan in Pts with Proteinuric Glomerular Diseases (Chinook)

Protocol Name: AFFINITY: Atrasentan in Pts with Proteinuric Glomerular Diseases

Sponsor: Chinook

Indication: Focal segmental glomerulosclerosis (FSGS)

Primary Investigator: Akinwande Akinfolarin, MD

Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (Otsuka)

Protocol Name: Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Sponsor: Otsuka

Indication: IgA Nephropathy

Primary Investigator: Dr. Bernard Fischbach

Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

DETAILS >

Immunoglobin nephropathy – IgA (Omeros)

Protocol Name: Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Sponsor: Omeros

Indication: IgA Nephropathy

Primary Investigator: Dr. Akinwande Akinfolarin

Location: 411 N Washington Ave, Suite 6000, Dallas, TX 75204

DETAILS >

Clinical research studies are necessary to prove that a medicine or treatment is both safe and effective.